您的位置: 首页 > 农业专利 > 详情页

Anti-CD3 Antibodies, Bispecific Antigen-Binding Molecules That Bind CD3 And CD20, And Uses Thereof
专利权人:
Regeneron Pharmaceuticals; Inc.
发明人:
Smith, Eric,Papadopoulos, Nicholas J.
申请号:
AU2020239677
公开号:
AU2020239677A1
申请日:
2020.09.23
申请国别(地区):
AU
年份:
2020
代理人:
摘要:
#$%^&*AU2020239677A120201015.pdf#####ABSTRACT The present invention provides antibodies that bind to CD3 and methods of using the same. According to certain embodiments, the antibodies of the invention bind human CD3 with high affinity and induce human T cell proliferation. The invention includes antibodies that bind CD3 and induce T cell-mediated killing of tumor cells. According to certain embodiments, the present invention provides bispecific antigen-binding molecules comprising a first antigen-binding domain that specifically binds human CD3, and a second antigen-binding molecule that specifically binds human CD20. In certain embodiments, the bispecific antigen-binding molecules of the present invention are capable of inhibiting the growth of B-cell tumors expressing CD20. The antibodies and bispecific antigen-binding molecules of the invention are useful for the treatment of diseases and disorders in which an upregulated or induced targeted immune response is desired and/or therapeutically beneficial. For example, the antibodies of the invention are useful for the treatment of various cancers as well as other CD20-related diseases and disorders.
来源网站:
中国工程科技知识中心
来源网址:
http://www.ckcest.cn/home/
相关发明人
相关专利

意 见 箱

匿名:登录

个人用户登录

找回密码

第三方账号登录

忘记密码

个人用户注册

必须为有效邮箱
6~16位数字与字母组合
6~16位数字与字母组合
请输入正确的手机号码

信息补充